Backed by Or­biMed, Lil­ly and now Ad­van­tech, Chi­na's In­ven­tis­Bio loads up $70M to pro­pel can­cer, meta­bol­ic pipeline

Al­most two years af­ter bag­ging a $19 mil­lion round for its ear­ly-stage R&D amid some sweep­ing re­forms in Chi­na’s reg­u­la­to­ry world, Shang­hai-based In­ven­tis­Bio is back on stage with $70 mil­lion in Se­ries C cash and a glob­al Phase II game plan.

Ad­van­tech Cap­i­tal and CM­BI — both rec­og­niz­able names in Chi­na — co-led the round, fol­lowed by Pudong In­notek. They join ex­ist­ing in­vestors Lil­ly Asia Ven­ture and Or­biMed Asia in back­ing a start­up boot­strapped by Mer­ck vet and com­pa­ny founder Yaolin Wang, who left the phar­ma gi­ant in 2015 to start In­ven­tis­Bio.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA